Us TOO Presents: Prostate Cancer Pathways
Prostate Cancer Pathways Event and Webcast
Presented by Us TOO
Recorded Saturday, November 9, 2019
at Northwestern Medicine, Robert H. Lurie Medical Research Center
Chicago, IL
VIDEO
With Presenting Experts:
Sean Sachdev, MD - Radiation Treatment Options & Potential/ Probable Side Effects
Maha Hussain, MD - Advanced Prostate Cancer & Clinical Trials
Nelson Bennett, Jr., MD - Moderator & Sexual Health After Prostate Cancer Treatment
Carmen Williams, MS, CGC - Genetics & Genomics
Shilajit D. Kundu, MD - Initial Diagnosis: Active Surveillance, Surgical Options, Potential/Probable Side Effects from Surgery
Alicia Morgans, MD, MPH - Moderator
David J. VanderWeele, MD, PhD - Molecular Testing & Bone Support
CLICK TIME FOR DIRECT LINK TO EACH SEGMENT BELOW
0:10 Intro - Chuck Strand, CEO of Us TOO
2:06 About Us TOO
4:53 Agenda
5:53 Intro to Session 1 Moderator Dr. Nelson Bennett
8:04 Dr. Nelson Bennett
8:20 Intro to Dr. Shilajit Kundu
9:04 Initial Diagnosis: Active Surveillance, Surgical Options & Side Effects
9:41 Scope of Problem
10:27 Incidence
12:41 Risk
13:19 Survival
14:00 PLCO Study of Screening
15:30 USPSTF
16:02 Chance of Localized Prostate Cancer
17:00 Risk of Dying of Prostate Cancer - Surgery v. Watchful Waiting
18:29 PROTECT Trial
19:13 USPSTF Change
19:54 Low Grade Prostate Cancer
20:46 Active Surveillance
23:46 Radical Prostatectomy
24:24 Surgery
26:10 Quality of Life After Prostatectomy - Erectile Function
27:14 Urinary Function
27:36 Bowel Symptoms
28:23 Conclusions
29:55 Intro to Dr. Sean Sachdev
30:43 Radiotherapy
32:30 History
34:46 Evolution of Treatment
36:10 Computerized MLCs (Beam Shaping)
37:18 Intensity Modulated Radiation Treatment
38:45 Arc IMRT - Volumetric Mediated Arc Treatment
40:47 Genitourinary Radiotherapy, Workflow
42:51 Stereotactic Radiotherapy, High Dose Ablative RT
44:05 GammaKnife
45:09 Computer Controlled, Frame-Free Approach
45:57 Applications
47:18 Updates
47:37 NCCN Risk Classification
48:08 Low Risk Treatment
49:15 Dose Escalation RTOG 0126
50:57 Androgen Deprivation Therapy & RT
55:22 Post-Operative Treatment, Radiotherapy
55:40 Adjuvant v. Salvage
56:07 Adjuvant RT Utilization
56:56 ADT
58:24 Androgen v. Salvage RT
1:00:15 Dr. Nelson Bennet - Prostate Cancer & the Penis
1:00:28 Post-RP Sexual Dysfunctions
1:01:01 ED After Prostatectomy
1:01:50 Anatomy
1:02:07 Nerve-Sparing Surgery
1:03:10 Radiation Therapy & ED
1:05:18 Importance of Sexual Function - Psychological Issues
1:05:48 ED & Depression
1:07:00 Erectile Function Recovery
1:09:54 Other Dysfunctions
1:10:00 Dysorgasmia
1:10:30 Orgasm-Associated Urine Leak
1:10:57 Penile Length Alterations
1:13:55 Peyronie's Disease
1:14:30 Treatments
1:14:52 Pills - Phosphodiesterase Type 5 Inhibitors
1:16:17 Vacuum Devices
1:17:20 Transurethral PGE (Muse)
1:17:50 Intracavernosal Injections
1:18:24 Penile Rehabilitation - Prophylactic Therapy
1:20:10 Surgical Options - Penile Prosthesis
1:22:12 Prosthesis - Advantages & Disadvantages
1:23:16 Intro to Cliff Whall, Us TOO Support Group Leader
1:24:29 Patient Perspective
1:43:30 Panel Discussion & Q&A
2:09:00 Intro to Sponsors
2:15:15 Intro to Session 2 Moderator - Dr. Alicia Morgans
2:17:11 Intro to Carmen Williams
2:18:54 Genetics
2:19:56 Genetic Counselors
2:21:50 Genetics 101
2:22:41 Terminology
2:23:59 How Genes Cause Cancer
2:24:33 Normal Human Genome
2:25:20 Somatic v. Germline
2:27:03 Distribution of Cancer
2:27:33 Genetics 201 - Hereditary Conditions
2:29:37 Genetic Counseling Consultations
2:30:31 When to Suspect Hereditary Prostate Cancer
2:31:45 Genes Associated with Hereditary Prostate Cancer
2:32:24 Possible Results
2:33:54 Considerations for Undergoing Genetic Testing
2:35:09 Family that is BRCA+
2:36:42 Genetic Discrimination
2:38:56 Take Home Points - Hereditary Genetic Testing
2:39:31 Genetics 301 - DNA Testing of Tumors
2:42:25 Goals of Somatic Testing
2:43:37 Results
2:44:44 Take Home Points - Somatic Tumor DNA Testing
2:45:18 Resources
2:46:52 Intro to Dr. Maha Hussain
2:48:53 Prostate Cancer Disease States
2:52:08 Metastatic Prostate Cancer
2:54:42 Hypothalamic-Pituitary-Gonadal Axis
2:55:20 Historical Perspective: Androgens & Prostate Cancer
2:56:27 Metastatic Hormone Sensitive Prostate Cancer
2:57:55 Landmarks of FDA Drug Approvals
3:01:16 Metastatic Castration Resistant Prostate Cancer Treatment Options
3:02:00 mCRPC Research Themes/Emerging Data
3:04:46 CARD Clinical Trial
3:05:28 Imaging-Based Progression-Free Survival, Estimates of Overall Survival & PFS
3:06:59 Precision Medicine
3:07:57 Genomic Landscape of SU2C Metastatic Castration Resistant Prostate Cancer
3:08:51 DNA Damage Response & PARP Inhibitors
3:09:56 PROfound Phase 3 Study of Olaparib v. Enzalutamide
3:13:27 Revisiting Chemohormonal & Combined Androgen Deprivation Strategies
3:14:02 CHAARTED
3:15:05 LATITUDE
3:15:40 ENZAMET
3:16:14 Metastatic Hormone Sensitive PCa
3:16:44 Prostate Cancer General Disease States
3:17:23 Non Metastatic Castration-Resistant Prostate Cancer
3:18:18 Demographic & Disease Characteristics at Baseline
3:18:36 Metastasis-Free Survival
3:19:33 Prostate Cancer Survival Over Time
3:21:03 Conquer Prostate Cancer Through Research & Excellence in Care
3:22:02 Dr. Alicia Morgans - Intro to Dr. David J. VanderWeele
3:23:28 Oncology
3:24:52 Why Consider Genomic/Molecular Testing
3:29:38 Homologous Recombination Pathway
3:33:47 Mismatch Repair Pathway
3:44:10 Bone Strength
3:47:16 Risk for Fractures
3:48:20 How Can You Prevent Fractures
3:50:21 Panel Discussion & Q&A
Thank You to Host: Northwestern Medicine, Robert H. Lurie Medical Research Center and Sponsors: Astellas, Pfizer Oncology, Amgen, Genomic Health, Clovis Oncology, Dendreon, Advanced Accelerator Applications, Foundation Medicine, Sanofi Genzyme, and Timm Medical Technologies Inc.